Biotech Values

[iwfal]

GERN - I think the most interesting part of the cc was the following:

Matthew J. Lowe - JP Morgan Chase & Co, Research Division
Okay. And then just as a quick follow-up. With the responses that are referred to in the abstract this morning, I mean, I guess, what is the definition of those responses? Are they according to the criteria that you mentioned? Or are they just kind of referring to responses specifically to do with the bone marrow and the blood?

John A. Scarlett - Chief Executive Officer, President and Director
I think I'm going to have to let you read the abstract for yourself and interpret it that way. I'm not going to be able to make any comments about that, sorry.

He knew it had multiple possible interpretations and chose not to clarify.